Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 29Carcinoma, Hepatocellular 2Thyroid Neoplasms 1Renal Insufficiency 1Prostate Adenocarcinoma 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Melanoma 1Carcinoma, Adenoid Cystic 1

Interventions

Dexamethasone 10Bortezomib 7Lenalidomide 4isatuximab 3Calcium Dobesilate 3pomalidomide 2Thalidomide 2Gemcitabine 2Cyclophosphamide 2vinflunine 1melflufen 1glucarpidase 1gallium 68 PSMA-11 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Tablets 1Ranitidine 1Pluvicto 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Eplerenone 1Doxorubicin 1Diphenhydramine 1Carboplatin 1Bendamustine Hydrochloride 1BHQ880 1Acetaminophen 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Renal Insufficiency × gallium 68 PSMA-11 × Clear all
NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Novartis

Phase 2 Recruiting
20 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡